S2 Ep38: Talking HER2-Targeted Therapy With Dr. Corcoran
We had the pleasure of speaking with Ryan Corcoran, MD, PhD, who discussed key takeaways regarding the use and investigation of HER2-targeted therapies in gastrointestinal malignancies. Listen on to hear Corcoran discuss the current testing standards and practice patterns surrounding the treatment of HER2-positive gastrointestinal malignancies and provide insight on the current understanding of...
10m Apr 03, 2020
10m
S2 Ep37: Dr. Marshall Calls for Continued Discourse on Physician Burnout in Oncology
We had the pleasure of speaking with John L. Marshall, MD, to discuss physician burnout in oncology. In our exclusive interview, Dr. Marshall provided his perspective on burnout in oncology, discussed the long-term personal and professional consequences of burnout, and shared ways to reduce oncology burnout on an individual and organizational level.
23m Apr 02, 2020
23m
S2 Ep36: Collaborative Efforts Lead to the Launch of the COVID-19 and Cancer Consortium Registry
Today, we passed the mic to Petros Grivas, MD, PhD, who moderated a discussion on a multi-institutional registry that has been created to capture data from healthcare professionals on patients with cancer who have suspected or confirmed diagnoses of the novel coronavirus, COVID-19. Joining Dr. Grivas is Jeremy L. Warner, MD, MS, principal investigator of the COVID-19 and Cancer Consortium Regis...
26m Mar 30, 2020
26m
S2 Ep35: FLASCO Faculty Flesh Out Case Studies in GI Cancers
We recently traveled to Miami, Florida, for a State of the Science Summit™ on Gastrointestinal Malignancies. Targeted therapy has become an important fixture in oncogene-driven cancers, particularly in BRAF V600E-mutant metastatic colorectal cancer and BRCA-mutant metastatic pancreatic cancer. Although the jury is still out on the actionability of a HER2 mutation versus HER2 overexpression or a...
48m Mar 25, 2020
48m
S2 Ep34: Spotlighting New Standards of Care in Lung Cancer in Summit
We recently traveled to Summit, New Jersey for a State of the Science Summit™ on Lung Cancer. At the meeting, faculty from Memorial Sloan Kettering Cancer Center shed light on early-stage interventions in lung cancer, the use of up-front next-generation sequencing, and predictive and prognostic biomarkers that are enhancing treatment decisions in non–small cell lung cancer. Faculty also spotlig...
26m Mar 18, 2020
26m
S2 Ep33: Maurie Markman, MD: Confronting the Complexities of Care in Gynecologic Cancers
We had the pleasure of sitting down with Maurie Markman, MD, physician and president of medicine and science at Cancer Treatment Centers of America—and the editor-in-chief of our flagship publication, OncologyLive.
31m Mar 11, 2020
31m
S2 Ep32: Navigating NGS and Novel Therapies in GI Malignancies in New York
We recently traveled to Brooklyn, New York, for a State of the Science Summit™ on Gastrointestinal Cancer. At the meeting, faculty from Weill Cornell Medical Center and Montefiore Medical Center discussed the importance of next-generation sequencing in advanced gastric and gastroesophageal junction cancer and explained that a deeper understanding of the biology of neuroendocrine tumors may be k...
30m Mar 04, 2020
30m
S2 Ep31: Talking Tumors: Turning to Liquid Biopsies and Immunotherapy in Lung Cancer
We recently traveled to Austin, Texas, for a State of the Science Summit™ on Lung Cancer. Immunotherapy, whether alone or in combination with chemotherapy, has become a frontline standard of care in advanced non–small cell lung cancer. While PD-L1 expression and the presence of molecular markers such as ALK and EGFR can help determine whether such an approach is recommended, results from PD-L1 ...
41m Feb 26, 2020
41m
S2 Ep30: Unpacking IO Innovations in Lung Cancer in Pittsburgh
We recently traveled to Pittsburgh, Pennsylvania, for a State of the Science Summit on Lung Cancer. At the meeting, faculty from the University of Pittsburgh Medical Center and Fox Chase Cancer Center discussed how chemoimmunotherapy has changed the standard of care in stage IV nonsquamous NSCLC, highlighted how up-front immunotherapy has become a pivotal part of treatment in squamous NSCLC, an...
23m Feb 19, 2020
23m
S2 Ep29: Jeffrey Weber, MD, PhD: Charting New Territories in Melanoma
In our exclusive interview, Jeffrey S. Weber, MD, PhD, shared with us his journey into the melanoma field and the lessons he has learned along the way, some of the key studies that have significantly impacted his career and clinical practice, and what lies ahead in the melanoma pipeline.
26m Feb 12, 2020
26m
S2 Ep28: Analyzing the Application of Precision Medicine in Austin
We recently traveled to Austin, Texas, for a State of the Science Summit™ on Precision Medicine. At the meeting, faculty from Texas Oncology provided updates on precision medicine initiatives in lung cancer and pancreatic cancer, including biomarkers and molecular testing.
22m Feb 05, 2020
22m
S2 Ep27: Talking Tumors: Contemplating Clinical Conundrums in Lung Cancer
We recently traveled to Newton, Massachusetts, for a State of the Science Summit™ on Lung Cancer. Immunotherapy and targeted therapy have become important treatment approaches to consider in advanced non–small cell lung cancer. Although biomarkers such as PD-L1 expression and EGFR mutations have helped refine which patient populations are best suited to each approach, several questions remain. ...
38m Jan 29, 2020
38m
S2 Ep26: Pondering Progress Made in GU Cancers in Phoenix
We recently traveled to Phoenix, Arizona for a State of the Science Summit™ on Genitourinary Cancers. At the meeting, faculty from Mayo Clinic and Banner MD Anderson Cancer Center highlighted how novel agents have revolutionized the nonmetastatic castration-resistant prostate cancer paradigm and explained how the PROfound data could lead to the first PARP inhibitor approval in metastatic castra...
26m Jan 23, 2020
26m
S2 Ep25: Collaboration Saves Lives: Managing irAEs is a "Dynamic Discussion"
Omid Hamid, MD, and Grace Cherry, NP, shared the importance of multidisciplinary care for patients with melanoma, how to best manage immunotherapy-related adverse events, and tips for developing trusting relationships with patients so that they feel comfortable reporting toxicities.
26m Jan 17, 2020
26m
S2 Ep24: Airing Treatment Advances in Breast Cancer in New York
We recently traveled to Long Island, New York, for a State of the Science Summit™ on Breast Cancer. At the meeting, faculty from NYU Langone’s Perlmutter Cancer Center shed light on how to balance genomic and clinical risk in hormone receptor¬–positive disease, novel approaches that are pushing the envelope in HER2-positive disease, and how tumor biology is being used to personalize surgical in...
30m Jan 08, 2020
30m
S2 Ep23: Stephanie Graff, MD: Information Is Power for Patients With Breast Cancer
Stephanie L. Graff, MD, shares the importance of personalizing care for patients with breast cancer, how she balances her professional and personal life, the techniques to using the optimal voice on social media, and her vision for the future of breast cancer treatment.
13m Jan 01, 2020
13m
S2 Ep22: Outlining Advances Made in Ovarian Cancer in Oklahoma City
We recently traveled to Oklahoma City, Oklahoma for a State of the Science Summit™ on ovarian cancer. At the meeting, faculty from Stephenson Cancer Center shed light on the necessity of PARP inhibitors in recurrent ovarian cancer, emerging strategies for PARP inhibitor resistance, and explained why neoadjuvant chemotherapy could be a safer alternative for certain patients. Additionally, facult...
23m Dec 25, 2019
23m
S2 Ep21: Talking Tumors: Weill Cornell Medicine Experts Walk Through Challenging Breast Cancer Cases
We recently traveled to New York City, New York for a State of the Science Summit™ on Breast Cancer, where we spoke with Lisa Newman, MD, MPH, FACS, FASCO, chief of Breast Surgery, Weill Cornell Medical Center and NewYork-Presbyterian, and Alan B. Astrow, MD, a professor of medicine at Weill Cornell Medicine, and chief of hematology and medical oncology at New York Methodist Hospital. In our di...
26m Dec 19, 2019
26m
S2 Ep20: Highlighting Progress Made in Hematologic Malignancies in Philly
We recently traveled to Philadelphia, Pennsylvania for a State of the Science Summit™ on Hematologic Malignancies. At the meeting, faculty from The University of Pennsylvania discussed updates in multiple myeloma, chronic lymphocytic leukemia, acute myeloid leukemia, acute lymphoblastic leukemia, mantle cell lymphoma, and non-Hodgkin lymphoma. Additionally, we heard about emerging treatment opt...
30m Dec 12, 2019
30m
S2 Ep19: Checking Out Emerging Approaches in Lung Cancer Treatment in Chicago
We recently traveled to Chicago, Illinois for a State of the Science Summit™ on Lung Cancer. At the meeting, faculty from the University of Chicago emphasized the impact of immunotherapy in non–small cell lung cancer, including the paradigm shift in the treatment of patients with stage III disease, promising combinations under exploration in stage IV nonsquamous disease, and key updates with th...
27m Dec 04, 2019
27m
S2 Ep18: Tanios Bekaii-Saab, MD: Not Just Seeing the Light, But Getting Out of the Tunnel
In our exclusive interview, Dr. Tanios Bekaii-Saab spent time discussing the path to practicing in gastrointestinal malignancies, how he navigates balancing his professional and personal life, and mottos he has lived by throughout his career and whilecaring for his patients.
29m Nov 27, 2019
29m
S2 Ep17: Reviewing Breakthroughs in Breast Cancer in Raleigh
We recently traveled to Raleigh-Durham, North Carolina for a State of the Science Summit™ on Breast Cancer. At the meeting, faculty from Duke Cancer Institute explained how prognostic and predictive assays are being used to guide treatment decisions in breast cancer, provided perspective on the optimal use of HER2-targeted therapy, antibody-drug conjugates, PARP inhibitors, and CDK4/6 inhibitor...
26m Nov 21, 2019
26m
S2 Ep16: Talking Tumors: Filling Data Gaps in Multiple Myeloma
We recently traveled to New York City, New York, for a State of the Science Summit™ on Multiple Myeloma. Although the treatment paradigm in multiple myeloma is guided by transplant eligibility, and grounded in the use of immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, certain elements of practice are not as well described. Therefore, we sat down with Ajai Chari, MD, ...
35m Nov 15, 2019
35m
S2 Ep15: Spotlighting New Standards in Lung Cancer in Salt Lake City
We recently traveled to Salt Lake City, Utah for a State of the Science Summit™ on Non–Small Cell Lung Cancer. At the meeting, faculty from the University of Utah and Intermountain Healthcare, delved into biomarker discoveries, research regarding the heredity of lung cancer, emerging treatment modalities, and practice-changing trials that have impacted the paradigm. Other topics included the ro...
40m Nov 07, 2019
40m
S2 Ep14: Howard "Skip" Burris, MD: A Passion for Befriending Patients and Always Being Kind
Howard A. Burris, MD, also known as Skip, of Sarah Cannon Research Institute, discussed how he wound up in the oncology space, his passion for getting to know and helping his patients, and some proud moments throughout his monumental career.
31m Nov 01, 2019
31m
S2 Ep13: Outlining Progress Made in Ovarian Cancer in Pittsburgh
We recently traveled to Pittsburgh, Pennsylvania for a State of the Science Summit™ on Ovarian Cancer. At the meeting, faculty from the University of Pittsburgh Medical Center highlighted the many advances made with PARP inhibitors, the importance of molecular testing, considerations for the frontline treatment of newly diagnosed disease, as well as the best options for neoadjuvant therapy. Fac...
34m Oct 24, 2019
34m
S2 Ep12: Talking Tumors: Adaptive Approaches in Triple-Negative and HR-Positive Breast Cancers
Jane L. Meisel, MD, and Aditya Bardia, MD, MPH, shed light on treatment considerations for women with triple-negative breast cancer (TNBC) who are candidates for neoadjuvant therapy, emerging treatment strategies for patients with metastatic TNBC, as well as the optimal timing of genomic testing in women with progressive hormone receptor–positive disease.
40m Oct 16, 2019
40m
S2 Ep11: Spreading Newfound Treatment Strategies in Hematologic Malignancies in Seattle
We recently traveled to Seattle, California for a State of the Science Summit™ on Hematologic Malignancies. At the meeting, faculty from Seattle Cancer Care Alliance provided insight on current and evolving standards of care in leukemia, lymphoma, and myeloma, highlighting particular targets of interest for novel therapies.
32m Oct 09, 2019
32m
S2 Ep10: Examining Major Breakthroughs Made in Breast Cancer in Milwaukee
We recently traveled to Milwaukee, Wisconsin, for a State of the Science Summit™ on Breast Cancer. At the meeting, faculty from Carbone Cancer Center of the University of Wisconsin highlighted the evolving paradigms across breast cancer subtypes and settings, such as early and advanced hormone receptor–positive breast cancer, early-stage HER2-positive breast cancer, and metastatic triple-negati...
25m Oct 02, 2019
25m
S2 Ep9: Perusing Progress Made in Ovarian Cancer Treatment Paradigm in Pasadena
We recently traveled to Pasadena, California, for a State of the Science Summit™ on Ovarian Cancer. At the meeting, faculty from City of Hope discussed the necessity of genetic testing as well as the latest data regarding the use of PARP inhibitors, immunotherapy, chemotherapy, and surgical debulking while explaining how these data can be interpreted in clinical practice.
29m Sep 23, 2019
29m
S2 Ep8: Maha Hussain, MD: Anything Is Possible With a Fire in the Belly
Maha Hussain, MD, FACP, FASCO, of Northwestern University Feinberg School of Medicine, reflected on the path that led her into genitourinary  cancers.
23m Sep 18, 2019
23m
S2 Ep7: Gaining Ground in GI Cancers in Denver
We recently traveled to Denver, Colorado, for a State of the Science Summit on Gastrointestinal Malignancies, which featured insights from University of Colorado and Rocky Mountain Cancer Centers faculty. Meeting topics spanned the importance of molecular testing in the management of newly diagnosed metastatic colorectal cancer, advances with biomarker-directed therapies and immunotherapies in ...
28m Sep 12, 2019
28m
S2 Ep6: Mapping Multiple Myeloma Advances in NYC
We recently traveled to New York City, New York, for a State of the Science Summit on Multiple Myeloma. We met with experts from Mount Sinai Hospital to gather updates on emerging treatment strategies in multiple myeloma, including headway made with CAR T-cell therapies, the role of genomics, the shift toward personalized medicine, and progress made with maintenance therapies.
31m Sep 04, 2019
31m
S2 Ep5: Garnering Breakthroughs in GU Cancers in Boston
We recently traveled to Boston, Massachusetts, for a State of the Science Summit™ on Genitourinary Cancers. At the meeting, experts from Dana-Farber Cancer Institute discussed the latest updates in prostate cancer, including the role of radiation, the question of androgen deprivation therapy–associated cardiac complications, and novel imaging modalities being used in nonmetastatic hormone-sensi...
33m Aug 29, 2019
33m
S2 Ep4: Mastering New Advances in Hematologic Malignancies in Milwaukee
We recently traveled to Milwaukee, Wisconsin for a State of the Science Summit™ on Hematologic Malignancies. We met with experts from the Medical College of Wisconsin to gather updates in acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, mantle cell lymphoma, and myeloproliferative neoplasms. Additionally, we heard the latest news surrounding chimeric antigen receptor T-ce...
24m Aug 20, 2019
24m
S2 Ep3: Talking Tumors: Leveraging Immunotherapy in Nonsquamous NSCLC
We recently traveled to Little Rock, Arkansas, for a State of the Science Summit™ on Non–Small Cell Lung Cancer. In advance of the meeting, we conducted a Twitter poll regarding the use of single-agent immunotherapy versus combination chemotherapy and immunotherapy in a patient with nonsquamous non–small cell lung cancer. During the meeting, we also asked our attendees to answer the poll to gau...
30m Aug 15, 2019
30m
S2 Ep2: Newfound Understandings of Neuroendocrine Treatment in Kentucky
We recently traveled to Lexington, Kentucky for a State of the Science Summit on Neuroendocrine Tumors. The meeting, led by experts from University of Kentucky Markey Cancer Center, spotlighted the latest management strategies in the treatment of patients with neuroendocrine tumors, starting with the diagnosis, classification, and staging of these tumors, to surgery and sequencing approaches wi...
27m Aug 07, 2019
27m
S2 Ep1: Perusing Breakthroughs in Breast Cancer in Pasadena
We recently traveled to Pasadena, California, for a State of the Science Summit on Breast Cancer. The meeting, which featured insight from experts from City of Hope, covered a wide array of topics, ranging from advances made in HER2-positive breast cancer, to key trials in metastatic triple-negative disease, to genomic assays used in hormone receptor–positive disease, to axilla management.
24m Jul 29, 2019
24m
S1 Ep50: Patrick I. Borgen, MD: From the Wild West of Breast Cancer Research to Chasing Cure
Patrick I. Borgen, MD, of Maimonides Medical Center, shares his live-by mottos as a breast cancer surgeon, a patient who defined his career, and what fuels his passion to fight breast cancer and remove opioid use after surgery.
33m Jul 24, 2019
33m
S1 Ep49: Navigating New Developments in NSCLC in Dallas
We recently traveled to Dallas, Texas for a State of the Science Summit on Non–Small Cell Lung Cancer. At the meeting, faculty from Baylor Scott and White Health System highlighted headway made in the treatment landscapes of non–small cell lung cancer according to histology, stage, and treatment intervention, the likes of which now include immunotherapy, targeted therapy, and chemotherapy.
22m Jul 20, 2019
22m
S1 Ep48: Tapping Into Great Progress Made in GI Cancers in Tampa
We recently traveled to Tampa, Florida, for a State of the Science Summit on Gastrointestinal Malignancies. At the meeting, faculty from Moffitt Cancer Center and Mayo Clinic reviewed the latest data in gastrointestinal oncology, covering all aspects of current care, from patient selection to the optimal timing of targeted therapy, immunotherapy, and chemotherapy, in neuroendocrine tumors, hepa...
27m Jul 14, 2019
27m
S1 Ep47: Hearing About Breakthroughs Made in Hematologic Malignancies in Boston
We recently traveled to Boston, Massachusetts, for a State of the Science Summit on Hematologic Malignancies, which featured insights from the faculty from Dana-Farber Cancer Institute. The meeting covered frontline approaches and sequencing challenges in multiple myeloma, key advances in mantle cell lymphoma, and novel agents in chronic lymphocytic leukemia. Experts also highlighted progress m...
21m Jun 25, 2019
21m
S1 Ep46: Discussing Pivotal Progress in Breast Cancer in Dallas
We recently traveled to Dallas, Texas, for a State of the Science Summit on Breast Cancer. During the meeting, faculty from Baylor Scott and White Health System and The University of Texas MD Anderson Cancer Center relayed the prognostic value of genomic assays in breast cancer and the scope of established and ensuing treatment approaches for those with early-stage and advanced disease.
17m Jun 18, 2019
17m
S1 Ep45: Contemplating Key Updates in GI Cancers in Charlotte
We recently traveled to Charlotte, North Carolina, for a State of the Science Summit™ on Gastrointestinal Cancers. During the meeting, the faculty shared expert insight on treatment approaches across metastatic colorectal cancer, locally advanced and metastatic pancreatic cancer, advanced hepatocellular carcinoma, neuroendocrine tumors, and advanced gastric cancer.
20m Jun 12, 2019
20m
S1 Ep44: Observing the Latest Developments in Ovarian Cancer in NYC
We recently traveled to New York City, New York, for a State of the Science SummitTM on Ovarian Cancer. During the meeting, the faculty shared their insight on the various surgical and medical treatment modalities in advanced ovarian cancer, as well as investigational interventions that may further define standards of care.
19m May 30, 2019
19m
S1 Ep43: Gaining Ground in GI Cancers in Durham
We recently traveled to Durham, North Carolina, for a State of the Science Summit™ on Gastrointestinal Malignancies. At the meeting, we spoke with the faculty from Duke Health and UNC Health Care, who highlighted key updates from the 2019 Gastrointestinal Symposium.
25m May 23, 2019
25m
S1 Ep42: Examining Key Breast Cancer Updates in Chicago
We recently traveled to Chicago, Illinois, for a State of the Science Summit™ on Breast Cancer. During the meeting, the faculty provided a comprehensive look into present and potentially future standards of care in early-stage and advanced breast cancer subtypes.
14m May 15, 2019
14m
S1 Ep41: Getting Up to Speed On Key Developments in GI Cancers in Washington DC
We recently traveled to Washington D.C. for a State of the Science Summit on Gastrointestinal Malignancies. During the meeting, the faculty spoke to the clinically diverse and steadily expanding therapeutic armamentariums for patients with gastrointestinal malignancies.
16m May 08, 2019
16m
S1 Ep40: Highlighting Pivotal Data From 2018 ASH Annual Meeting
We recently traveled to Kansas City, Missouri, for a State of the Science Summit™ on Hematologic Malignancies. The meeting provided a comprehensive snapshot of the pivotal data that were presented at the 2018 ASH Annual Meeting, spanning several diseases, such as multiple myeloma, chronic lymphocytic leukemia, acute myeloid leukemia, and much more.
19m May 01, 2019
19m
S1 Ep39: Talking Tumors: MSK Faculty Highlight Ovarian Cancer Cases
We recently traveled to New York City for a State of the Science SummitTM on Ovarian Cancer and Soft Tissue Sarcoma. In keeping up with the constant and sometimes controversial landscape of ovarian cancer, we sat down with Mario M. Leitao Jr, MD, FACOG, FACS, and Dmitriy Zamarin, MD, PhD, of Memorial Sloan Kettering Cancer Center, to discuss two common clinical scenarios faced in practice, and ...
32m Apr 25, 2019
32m